Therefore, several novel agents have been, or are currently being evaluated, including drugs targeted against the epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and different kinases involved in cancer proliferation (Kindler, 2008). This evidence concerns the gene EGFR and cancer.